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Aims Patients with diabetes have increased risk of in-stent restenosis after coronary stent implantation owing to neointimal
hyperplasia (NIH). The aim of the study was to evaluate the extent and distribution of NIH with intravascular ultra-
sound (IVUS) after coronary artery stenting with sirolimus-eluting (Cypher) or paclitaxel-eluting (Taxus) stents in
diabetic patients.
Methods
and results
One hundred and thirty diabetic patients were randomized to Cypher or Taxus stent implantation. IVUS was per-
formed at 8 month follow-up. NIH volume was significantly reduced in the Cypher group when compared with
the Taxus group: median (inter-quartile range) 0.0 (0.0–0.0) vs. 8.0 mm3 (0.1–33.0), P, 0.001. Per cent NIH
volume was also significantly lower in Cypher stents compared with Taxus stents: median (inter-quartile range)
0.0 (0.0–0.0) vs. 7.5% (0.1–27.0), P, 0.001. NIH was covering 5.4% of the stent length in the Cypher stents com-
pared with 46.1% in the Taxus stents (P, 0.001). The incidence of diffuse NIH was significantly higher for Taxus than
for Cypher stents (42.9 vs. 3.5%, P, 0.001). Taxus stents had more often NIH at the proximal stent edge compared
with Cypher stents (45.1 vs. 7%, P, 0.001) and no Cypher stents had NIH at the distal stent edge compared with
35.5% of the Taxus stents (P, 0.001).
Conclusion In diabetic patients, the Cypher stent, compared with the Taxus stent, inhibited NIH more effectively and had a more
focal NIH pattern including less involvement of the stent edges.
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Introduction
Diabetes mellitus is an important risk factor for poor outcome
after percutaneous coronary interventions (PCI) using bare metal
stents.1–3 A more diffuse and accelerated form of atherosclerosis
accompanied by smaller vessel size, long lesions, and greater
plaque burden in diabetic patients may contribute to the well-
documented increased risk of neointimal hyperplasia (NIH) and
restenosis after stent implantation in these patients.4–7 Drug-
eluting stents are highly effective in reducing in-stent restenosis
compared with bare metal stents, both in patients with and
without diabetes.8–19 Intravascular ultrasound (IVUS) has
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documented reduced NIH,14–18 and angiography has shown
reduced late lumen loss8,9 after coronary drug-eluting stent
implantation compared with bare metal stents. Recently, a
meta-analysis showed that sirolimus-eluting stents were more
effective than paclitaxel-eluting stents with regard to restenosis
in non-diabetic patients but appeared to be comparable in patients
with diabetes.20 Currently, only one randomized study has com-
pared the first two commercially available drug-eluting stents, i.e.
the sirolimus-eluting Cypher stent and the paclitaxel-eluting
Taxus stent in diabetic patients.21 The present study is the first ran-
domized multicentre IVUS study comparing NIH formation and
distribution within the stent in diabetic patients treated with the
Cypher stent vs. the Taxus stent.
Methods
Study population
From February 2005 to March 2006, 130 patients with diabetes melli-
tus and angiographically significant coronary stenoses in native coron-
ary arteries (vessel diameter 2.25–4.0 mm) were enrolled in a
non-blinded, randomized multicentre IVUS study at four Danish inter-
ventional centres (the DiabeDES study). The study is a substudy of
the SORT OUT II trial22 (Clinicaltrials.gov Identifier: NCT00388934).
A flow diagram of the study is shown in Figure 1. Exclusion criteria
were lesions in vein grafts. All patients provided written informed
consent, and the local institutional review board (The Scientific
Ethics Committee for the County of Aarhus, Denmark) approved
the protocol (case no. 20040170).
Randomization, study lesion, and
intervention
Patients were randomly assigned to receive a sirolimus-eluting (Cypher
Select; Cordis, Johnson & Johnson) or a paclitaxel-eluting stent (Taxus
Express-2, Boston Scientific) by telephone contact to a computer-
generated randomization sequence. The randomly assigned stent was
implanted in all lesions treated. In multivessel intervention, lesion
location in the left anterior descending coronary artery was selected
as study lesion. In combined circumflex and right coronary artery inter-
vention, the right coronary lesion was used as study lesion. If more
than one lesion was treated in the same vessel, the proximal lesion
was chosen as a study lesion. Only one lesion (study lesion) for each
patient was analysed according to this lesion selection. During the ran-
domization procedure, the diabetic patients were stratified according
to participation in the DiabeDES substudy. Prior to intervention, the
patients were treated with a 300–600 mg clopidogrel loading dose
and continued treatment with aspirin 75 mg daily. Unfractionated
heparin was given intravenously at the beginning of the procedure.
Glycoprotein IIb/IIIa inhibitors were used at the operator’s discretion.
After the intervention, clopidogrel 75 mg per day and aspirin 75 mg
per day were continued for 12 months and lifelong, respectively.
IVUS was performed at 8 month follow-up.
Intravascular ultrasound imaging protocol
and analysis
IVUS was performed after the administration of 200 mg intracoronary
nitroglycerin. The IVUS system (Galaxy or Clearview, Boston Scientific,
Fremont, CA, USA) utilized a 40 MHz, 2.6 Fr IVUS catheter (Atlantis-
Pro). Image acquisition using automated transducer pullback at
0.5 mm/s was performed from a point at least 10 mm distally to the
stent to the aorto-ostial junction. Offline analysis was performed
with a commercially available program for computerized planimetry
(EchoPlaque, INDEC System, Mountain View, CA, USA) by an inde-
pendent core laboratory (Odense University Hospital). Reproducibility
for geometrical measurements in the Odense University Hospital has
previously been published.23,24 All IVUS core laboratory analyses were
performed blinded to the treatment arm. Lumen, stent, and EEM
cross-sectional areas (CSAs) were measured within the stent.25 The
proximal and distal stent edge was the most proximal and distal
image CSA, respectively, within the stent. NIH was calculated as
stent minus lumen measures at follow-up. Per cent NIH volume was
defined as (NIH volume divided by the stent volume) multiplied by
100. The patterns of NIH were classified as focal (10 mm in
length) or diffuse (.10 mm in length). Peri-stent plaque CSA was cal-
culated as EEM CSA minus stent CSA in stented segments. Volumes
were calculated using Simpson’s rule.
Study endpoints
The primary endpoint of the study was in-stent NIH volume. Second-
ary endpoints were in-stent NIH percentage volume, patterns of NIH
(focal or diffuse), and NIH at the stent edges. The clinical endpoints,
namely total death, cardiac death, ST-segment elevation myocardial
infarction (MI), non-ST-segment elevation MI, target lesion
Figure 1 Flow diagram of the study.
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revascularization by PCI or coronary artery bypass grafting (CABG),
and ARC-defined stent thrombosis,26 were assessed although the
study was not powered to compare clinical events. All endpoints
were evaluated blinded to treatment arm.
Statistical analysis
The statistical analysis was carried out using SPSS 15.0. Categorical data
were presented as counts and percentages and compared by the
Pearson x2 test or the Fisher exact test. For continuous variables
with a normal distribution, the mean+1 SD was reported. For vari-
ables not normally distributed, the median and inter-quartile ranges
were reported. Continuous variables were compared using a Mann–
Whitney test or a Student’s t-test. Estimates of the differences
between the groups [and associated 95% confidence interval (CI)]
for the primary and secondary endpoints of interest are presented.
The sample size calculation was based upon an estimated NIH of 5%
in the Cypher stent group and 10% in the Taxus stent group with an
SD of 10%, alpha error of 0.05, and a power of 80%. Thus, a
minimum of 126 patients was pre-specified for enrolment. For the
primary endpoint, IVUS data will be available only for patients return-
ing for a follow-up IVUS after 8 months. Patients without IVUS data
were excluded from the intention-to-treat analysis. The reasons for
dropouts and proportions for each group have been reported. A sen-
sitivity analysis has been carried out, including patients with occluded
stent (estimating per cent NIH to be 100%). Estimating the remaining
non-available cases would, from a clinical point of view, be incorrect.
For the clinical endpoints, the data set will be 100% completed.
Thus, according to ICH E9, the full analysis set have been used.
Results
Clinical characteristics
We randomized 130 patients to Cypher stent (n ¼ 68) or Taxus
stent implantation (n ¼ 62). Follow-up IVUS was not performed
for clinical or technical reasons in 14 patients: (i) four patients
had TLR without IVUS before the scheduled 8 month follow-up,
(ii) three patients had an occluded study lesion at 8 month
follow-up, (iii) two patients had suboptimal follow-up IVUS
quality, (iv) two patients had only angiography performed at
follow-up, and (v) three patients died before the 8 month
follow-up. Finally, eight patients declined to have the 8 month
follow-up examination performed (Cypher n ¼ 4, Taxus n ¼ 4).
Thus, follow-up IVUS was available in 108 (83%) patients
(Cypher stent n ¼ 57, Taxus stent n ¼ 51). The Clearview IVUS
console was used in 10 patients, and the Galaxy IVUS console
was used in the other 98 patients. The baseline characteristics of
the completers were comparable with those not evaluated by
IVUS at 8 month follow-up. The clinical features at baseline are
shown in Table 1.
Lesion and stent characteristics
The lesion and stent characteristics are shown in Table 2. Baseline
angiographic reference vessel size, minimal lumen diameter, dia-
meter stenosis, stent size, and stent length did not differ significantly
between the two groups. The number of treated vessels was also
similar in the two groups. Also, the rate of pre-dilation and post-
dilation did not differ significantly between the Cypher- and the
Taxus-treated patients. In both groups, half of the patients were
treated with glycoprotein IIb/IIIa inhibitor at the index procedure.
Intravascular ultrasound measurements
IVUS volumetric measures for patients with 8 month follow-up
IVUS are shown in Table 3. At 8 month follow-up, EEM, stent,
and lumen volumes were similar in the Cypher and Taxus
groups (Figure 2).
Neointimal hyperplasia
At the 8 month follow-up, no NIH could be detected in 46 (81%)
of the Cypher stents compared with 11 (22%) of the Taxus stents
(P, 0.001). NIH volume [median (inter-quartile range) 0.0 (0.0–
0.0) vs. 8.0 mm3 (0.1–33.0), P, 0.001; mean difference
216.4 mm3 (95% CI) 221.9 to 211.0, P, 0.001)] and per cent
NIH volume [median (inter-quartile range) 0.0 (0.0–0.0) vs. 7.5%
(0.1–27.0), P, 0.001; mean difference 211.4% (95% CI 215.1
to 27.8), P, 0.001] were significantly lower in Cypher stents
compared with Taxus stents (Figure 3). Including the three patients
with occluded stent (estimating per cent NIH volume to be 100%),
the per cent NIH volume was [median (inter-quartile range) 0.0%
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical characteristics
Cypher (n5 68) Taxus (n 5 62) P-value
Male gender, n (%) 57 (83.8) 49 (79.0) 0.506
Age, years 62.6+9.1 64.4+8.4 0.248
Stable angina pectoris, n (%) 45 (66.2) 46 (74.2) 0.319
Diabetes type 2, n (%) 56 (82.4) 53 (85.5) 0.628
Insulin treatment, n (%) 29 (42.6) 24 (38.7) 0.722
Prior PCI, n (%) 10 (14.7) 14 (22.6) 0.248
Prior CABG, n (%) 4 (5.9) 1 (1.6) 0.206
Hypertension, n (%) 43 (63.2) 44 (71.0) 0.421
Hypercholesterolaemia, n (%) 59 (86.8) 58 (93.5) 0.355
HgbA1c, mmol/L 0.078+0.013 0.074+0.012 0.129
Body mass index, kg/m2 30.2+5.5 28.4+5.2 0.060
Smoking, n (%) 26 (38.2) 16 (25.8) 0.139
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(0.0–0.0)] in the Cypher stent group compared with 7.7% (0.7–
26.4), P, 0.001, in the Taxus stent group, mean difference
29.8% (95% CI 216.6 to 22.9), P ¼ 0.006.
Patterns of neointimal hyperplasia
distribution
NIH was covering 5.4+ 13.7% of the stent length in the
Cypher stents compared with 46.1+38.0% in the Taxus stents
(P, 0.001) [median (inter-quartile range) 0.0 (0.0–0.0) vs. 41.7%
(8.8–87.0), P, 0.001; mean difference 240.6% (95% CI 251.2
to 230.0), P, 0.001] (Figure 4). Evaluating only stents with NIH,
28.0+ 18.7% of the stent length in the Cypher stents compared
with 59.1+32.9% in the Taxus stents (P ¼ 0.004) was covered.
The incidence of diffuse NIH was significantly higher for Taxus
than for Cypher stents (42.9 vs. 3.5%, P, 0.001) (Figure 5). Also,
the incidence of focal NIH was significantly higher for Taxus than
for Cypher stents (34.7 vs. 18.8%, P, 0.001). The Taxus stents did
still have more diffuse NIH than the Cypher stents when only
stents with NIH were evaluated (55.3 vs. 18.2%, P ¼ 0.042).
Proximal and distal stent edges
The analysis of the proximal and distal stent edges showed a sig-
nificant difference between the two stent groups. NIH at the
proximal stent edge was more often seen in Taxus stents com-
pared with Cypher stents (45.1 vs. 7%, P, 0.001). The mean
per cent NIH volume at the most proximal stent CSA was
13.9% in the Taxus stent group compared with 1.5% in the
Cypher stent group (P, 0.001) [mean difference 212.4% (95%
CI 217.8 to 27.0), P, 0.001]. None of the Cypher stents
had NIH at the distal stent edge compared with 35.5% of the
Taxus stents (P, 0.001). The number of lesions with NIH at
the proximal stent edge was not significantly higher for post-
dilated lesions compared with lesions without post-dilatation
(31.4 vs. 21.9%, P ¼ 0.344).
Clinical events
Eight month clinical outcome was available in all patients (n ¼ 130,
100%). The incidence of major adverse cardiac events did not differ
in the two groups (Table 4). There were no definite stent throm-
boses. Three patients died during the follow-up period. One
patient died of a verified pancreas cancer. The two other patients,
one in each group, died suddenly (86 days and 285 days after index
PCI). Both cases were classified as cardiac death and thus as poss-
ible stent thrombosis. Autopsy was not performed in any of the
patients.
Discussion
This is the first randomized multicentre IVUS comparison of the
Cypher vs. the Taxus stent in diabetic patients. We found that
the NIH response differed between patients treated with Cypher
or Taxus stents. Thus, the Taxus stent generated more NIH and
had more diffuse NIH when compared with the Cypher stent.
Also, the NIH at the proximal stent edge was more often seen
in Taxus stents compared with Cypher stents, and at the distal
edge, NIH was seen only in the Taxus stents.
Inhibitory effect on neointimal
hyperplasia
The Cypher stent showed a significant inhibition of NIH compared
with the Taxus stent. No NIH could be detected by IVUS in 85% of
the Cypher stents compared with 24% of the Taxus stents. NIH is
the main component of in-stent restenosis after stent implantation
and reflects the degree of neointimal proliferation.27 The per cent
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Lesion and procedural characteristics
Cypher
(n5 68)
Taxus
(n5 62)
P-value
Number of treated lesions
per patient
0.884
1 39 (57.4) 38 (61.3)
2 21 (30.9) 19 (30.6)
3 8 (11.8) 5 (8.1)
Bifurcation lesions, n (%) 9 (13.2) 8 (12.9) 0.955
Pre-dilatation, n (%) 51 (75.0) 46 (74.2) 0.916
Post-dilatation, n (%) 23 (33.8) 18 (29.0) 0.557
GP IIb/IIIa inhibitors, n (%) 35 (51.5) 30 (48.4) 0.725
Number of stents per lesion 1.4+0.8 1.3+0.8 0.482
Lesion length, mm 20.3+14.6 17.7+10.5 0.264
Stent length, mm 24.5+15.0 22.5+13.1 0.408
Stent size, mm 3.1+0.4 3.1+0.4 0.381
Pre-intervention
Minimal lumen diameter,
mm
0.82+0.48 0.80+0.60 0.845
Reference diameter, mm 2.81+0.66 2.79+0.57 0.852
Diameter stenosis, % 70.1+16.3 71.1+20.1 0.767
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Volumetric intravascular ultrasound
measurements at 8 month follow-up
Cypher
(n 5 57)
Taxus
(n 5 51)
P-value
EEM, mm3 307.1+149.2 300.4+139.0 0.810
Stent, mm3 141.1+79.5 138.9+62.7 0.872
Lumen, mm3 138.8+76.7 121.7+59.8 0.203
Peri-stent plaque, mm3 169.1+78.8 161.1+80.0 0.604
Neointima, mm3
Mean (SD) 1.3+3.6 17.7+20.5 ,0.001
Median
(inter-quartile range)
0.0 (0.0–0.0) 8.0 (0.1–33.0) ,0.001
Percentage NIH volume
Mean (SD) 1.0+3.0 12.5+13.4 ,0.001
Median
(inter-quartile range)
0.0 (0.0–0.0) 7.5 (0.1–27.0) ,0.001
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neointimal free length of the stents, a measure of NIH homogen-
eity, measured 95% in the Cypher stents group compared with
54% in the Taxus stent group. Quantification of focal and diffuse
NIH distribution did also demonstrate significantly more diffuse
NIH in the Taxus stent group. For the Taxus stent, the per cent
neointimal free length of the stents is comparable with studies in
non-diabetics or studies containing a limited number of diabetic
patients.28,29 This study is in accordance with a previous random-
ized angiographic study comparing the effect of Cypher and Taxus
stent treatment in diabetic patients.21 Here, the paclitaxel stent
was associated with a higher rate of in-segment late luminal loss
compared with the sirolimus stent. An IVUS study diabetic
patients15 treated with sirolimus-eluting stents showed similar
NIH volume and per cent NIH volume as the Cypher stent
group in this study. Also, the NIH in this study is concordant
with the TAXUS-I,30 TAXUS-II,16,31 and TAXUS-IV16 studies in
non-diabetics or a limited number of diabetic patients where per
cent NIH volume was 14.8, 7.8, and 12.2%, respectively. In con-
trast, in earlier IVUS substudies, sirolimus-eluting stents have
been characterized by the near absence of measurable in-stent
tissue17,27 remaining minimal with long-term follow-up.32 The dia-
betic subpopulation in the RAVEL study showed a similar low per
cent NIH volume as the patients treated with Cypher stents in this
study.14
Figure 2 Cumulative distribution curve of (A) stent volume and (B) in-stent lumen volume at follow-up.
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Proximal-edge neointimal hyperplasia
is more common than distal-edge
neointimal hyperplasia
Restenosis after treatment with sirolimus- and paclitaxel-eluting
stents appears to occur more frequently at the margins of the
DES.27,33,34 Especially, the proximal stent-edge seems to have a
higher incidence of restenosis,33,34 which may be more pro-
nounced in paclitaxel stents.33,35 This is concordant with the
results of this study, where the proximal stent edge more
often was covered by NIH than the distal stent edge. Also,
NIH at the proximal stent edge was more frequent in Taxus
than in Cypher stents and resulted in a smaller CSA of the
proximal stent. At the distal stent edge, only Cypher stents
were free from NIH. In the TAXUS II study,18 it was demon-
strated that longitudinal distribution of NIH throughout the
stent was uniform with an increased amount of NIH from
distal to proximal in the stent. The reason for this observation
is not clear. The number of post-dilations did not differ
between the two groups. A uniformly distributed neointima
along the stent would indicate a homogeneous longitudinal
drug diffusion pattern from the stent. The vessel diameter is
Figure 3 Cumulative distribution curve of (A) in-stent neointimal hyperplasia volume at 8 month follow-up, (B) percentage neointimal hyper-
plasia volume at follow-up. Although stent volume is similar, the neointimal hyperplasia and per cent of obstruction volume curves are signifi-
cantly shifted to the left for the Cypher stent group.
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likely to be smaller at the distal part of the stented segment and
would theoretically receive a greater barotrauma and balloon
injury. However, this does not seem to influence NIH in DES
in general.
It should be emphasized that the axial resolution of IVUS is
200 mm and does not permit any assessment of the endothe-
lialization of the stent. A small amount of NIH may theoretically
reduce the risk of stent thrombosis by covering the stent
struts without leading to restenosis. Therefore, the observed
differences between the Cypher and the Taxus stents should
not be interpreted as evidence of differences with regard to clini-
cal endpoints such as restenosis and TLR. However, since NIH
results in a proportionally higher grade diameter stenoses in
small as opposed to large vessels, and diabetic patients more
often have smaller vessels, the more potent suppression of
NIH associated with Cypher stents, compared with Taxus
Figure 4 Cumulative distribution curve of the length of stent with neointimal hyperplasia.
Figure 5 The distribution of focal and diffuse neointimal hyper-
plasia and of stents without neointimal hyperplasia.
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Table 4 Clinical events at 8 month follow-up
Cypher
(n5 68)
Taxus
(n5 62)
P-value
Death (all cause) 2 1
Cardiac death 1 1
Definite stent thrombosis 0 0
Probable stent thrombosis 0 0
Possible stent thrombosis 1 1
MI 0 2
ST-segment elevation MI 0 0
Non-ST-segment elevation MI 0 2
Target lesion revascularization 1 3
PCI 0 2
CABG 1 1
MACE 3 6 0.309
PCI at follow-up procedure after
IVUS acquisition
3 6
MACE denotes major adverse cardiac events and includes cardiac death, MI, stent
thrombosis, and target lesion revascularization.
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stents, is in accordance with the clinical outcome in diabetic
patients in the SIRTAX trial.36
Limitations
The interpretation of this study requires consideration of several
limitations. First, only per cent NIH volume can be determined
by follow-up IVUS. Per cent NIH volume is a measure of efficacy,
as the detection of incomplete stent apposition and edge effects
would require both post-implantation and follow-up IVUS.
Second, lesions with total occlusion (n ¼ 3) or patients having
TLR before the scheduled 8 month follow-up were not assessed
with IVUS follow-up.
Conclusions
In diabetic patients, direct comparison of Cypher and Taxus stents
shows that the Cypher stent inhibits NIH more effectively than the
Taxus stent. Further, the Taxus stent has more frequent diffuse
NIH involvement of the stent edges.
Conflict of interest: none declared.
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